Description: Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women's health, and gastrointestinal diseases. The company's products for infectious diseases include QuickVue influenza test to detect viral antigens of influenza type A and B; QuickVue Strep A tests to detect Group A Streptococcal antigen from throat swabs or confirmation of presumptive Group A Streptococcal colonies recovered from culture; QuickVue RSV test, a rapid immunoassay for respiratory syncitial virus; and cell culture and DFA detection solutions to detect seven viral respiratory pathogens. It also offers cell-based products in various formats, including tubes, shell vials, and multi-well plates to culture and test for human viruses; ELVIS HSV system for the isolation and detection of herpes simplex virus (HSV) types 1 and 2; and a multiplex cell culture solution to isolate HSV, varicella zoster virus, and cytomegalovirus, as well as provides various analyzers and molecular assays. The company's products for women's health consist of QuickVue and RapidVue pregnancy tests to detect human chorionic gonoadotropin in serum or urine for the early detection of pregnancy; Thyretain for the diagnosis of graves, an autoimmune disease; QuickVue Chlamydia test to detect chlamydia trachomatis from endocervical swab and cytology brush specimens; and clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation, including metabolic bone markers to monitor the effectiveness of therapy in pharmaceutical and related research. In addition, it provides a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; and Helicobacter pylori tests, as well as develops diagnostic and research products in the fields of oncology, bone health, and autoimmune diseases. The company was founded in 1979 and is headquartered in San Diego, California.
Home Page: www.quidelortho.com
QDEL Technical Analysis
9975 Summers Ridge Road
San Diego,
CA
92121
United States
Phone:
858 552 1100
Officers
Name | Title |
---|---|
Mr. Douglas C. Bryant | Chairman & CEO |
Mr. Robert J. Bujarski J.D. | Pres & COO |
Ms. Michelle A. Hodges | Gen. Counsel |
Dr. Werner Kroll Ph.D. | Sr. VP of R&D |
Mr. Joseph M. Busky CPA | Chief Financial Officer |
Ms. Louise Brandy | Chief Information Officer |
Mr. Patrick E. Klein | Chief Admin. Officer |
Ruben Argueta | Director of Investor Relations |
Mr. Michael S. Iskra | Chief Commercial Officer |
Phillip S. Askim | VP, Associate Gen. Counsel & Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Health Care Supplies |
Forward PE: | 16.4745 |
---|---|
Trailing PE: | 5.1755 |
Price-to-Book MRQ: | 1.1627 |
Price-to-Sales TTM: | 1.8735 |
IPO Date: | 1991-02-01 |
Fiscal Year End: | December |
Full Time Employees: | 1600 |